HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Continues Cannabinoid Analysis Required In FY2021 Budget

Executive Summary

FDA is testing cannabidiol and other cannabinoids for whether labeled amounts match what’s in a product, says CFSAN Deputy Director Doug Stearn. The work is supported with $5m provided in the agency’s FY21 appropriation.

You may also be interested in...



Congressional Research Suggests Additional Layer Of Complexity In FDA’s Cannabinoid Puzzle

Congressional Research Service report says in addition to markets for hemp from fiber, seeds and flowers, “a separate, marketable category exists for the plant’s extracted compounds.” Ingredients from hemp seeds and grains as well as from flowers are alternative protein sources in supplements, foods and beverages and dairy alternatives.

US FDA Priorities For Food Safety, Cannabinoid Clear Even With Next Commissioner Unknown

FDA commissioner should be announced by mid-November and will likely continue to prioritize food and supplement safety, propelled by contaminants found in baby food, say two attorneys with Alston & Bird. A regulatory pathway for cannabidiol also is expected to be a priority once a commissioner is named.

DSM Remodels Nutrition Business With Fundamental Piece – Cannabinoid Ingredients

Royal DSM and Colorado’s Mile High Labs partner to provide companies in supplement, food and beverage sectors with ingredients to develop formulations with CBD and other cannabinoids. They initially are targeting the US and look to enter Canada, South America, Europe and Australia.

Related Content

Topics

UsernamePublicRestriction

Register

RS151346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel